• Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney Invest Now master your money
Moneycontrol

Home » News » Business

Feb 17, 2017, 10.33 AM | Source: CNBC-TV18

Biocon chief sees anti-cancer biosimilar launch in FY19

Biocon Thursday announced the US Food and Drug Administration has accepted Mylan’s Biologics License Application (BLA) for biosimilar chemotherapy drug Pegfilgrastim for review. Sharing details on the development with CNBC-TV18 Biocon Chairperson and Managing Director Kiran Mazumdar Shaw said, "This is a very important acceptance."

Like this story, share it with millions of investors on M3

Biocon chief sees anti-cancer biosimilar launch in FY19

Biocon Thursday announced the US Food and Drug Administration has accepted Mylan’s Biologics License Application (BLA) for biosimilar chemotherapy drug Pegfilgrastim for review. Sharing details on the development with CNBC-TV18 Biocon Chairperson and Managing Director Kiran Mazumdar Shaw said, "This is a very important acceptance."

Post Your Comments

Share Cancel

Kiran Mazumdar Shaw (more)

CMD, Biocon |

Biocon Thursday announced the US Food and Drug Administration has accepted Mylan’s Biologics License Application (BLA) for biosimilar chemotherapy drug Pegfilgrastim for review. Mylan is Biocon’s partner for biosimilar development.

Sharing details on the development with CNBC-TV18 Biocon  Chairperson and Managing Director Kiran Mazumdar Shaw said, "This is a very important acceptance."

However, the drug will not be launched immediately as there could be certain patent challenges, she added.

She expects the launch in financial year 2018 or 2019.

She said the USD-3.5-billion US market, is the biggest for the company and that biosimilars will contribute to company’s topline growth exponentially.

Pegfilgrastim is an anti-cancer drug used to reduce the chance of infection due to low white blood cell count and incidence of fever in people treated with chemotherapy in certain types of cancer.

This is the second Biocon application accepted by USFDA. Earlier, the drug regulator had accepted Mylan-Biocon’s application for biosimilar trastuzumab, used in the treatment of breast cancer.

In a stock exchange filing, Biocon said the goal date set by the US FDA under the Biosimilar User Fee Act is 9 October, 2017.

Buy, Hold, Sell ? Hear it first on M3
Biocon chief sees anti-cancer biosimilar launch in FY19

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login